Discovery & history

• Why CJC-1295 is really two different drugs (DAC vs no-DAC)
• How a maleimide and albumin turn 30 minutes into a week
• What the one ConjuChem trial program actually showed, and where it stopped
• How to read community stacking and dosing claims critically

1. 01 Discovery & history One name, two very different molecules free
2. 02 Chemistry & structure Four swaps and a hook: the molecule in detail paid
3. 03 The DAC albumin trick How a chemical hook borrows a week of half-life paid
4. 04 The GH and IGF-1 axis One receptor upstream, a cascade downstream paid
5. 05 Pulsatile versus sustained GH A rhythm amplified, or a baseline raised paid
6. 06 The clinical evidence One short program, read honestly paid
7. 07 The CJC + ipamorelin stack Two receptors, one coordinated push paid
8. 08 Compared to other GH-axis drugs One family, several very different tools paid
9. 09 Product quality & regulation The label problem, and the legal reality paid
10. 10 Dosing & Administration What the community reports, read critically paid
11. 11 Safety & Side Effects Real short-term signals, large long-term unknowns paid
12. 12 Final Exam & Certification Pass the final exam to earn your specialist certificate. exam

The story of CJC-1295 is the story of a single engineering problem: natural GHRH is destroyed within minutes, so making it useful meant making it last. Early GHRH drugs like sermorelin still needed frequent dosing. ConjuChem set out to build a version that could be given once a week, and along the way created two versions with wildly different durations. The timeline marks the key beats.

Read this as a story that stops early. CJC-1295 reached healthy-adult pharmacology and a partial patient trial, then development ended and the molecule drifted into the gray-market research economy. Almost everything said about it since rests on that small published base plus extrapolation from cousins like tesamorelin.

Strip away the branding and CJC-1295 is GHRH(1-29), the active core of natural GHRH, carrying four small amino-acid swaps for stability. The DAC version adds one more piece: a chemical linker that grabs albumin. The derivation shows the natural 29-residue core the drug keeps, and the numbers card summarizes the molecule at a glance.

Those four swaps are not cosmetic. They block the enzyme that destroys natural GHRH and stop the peptide from degrading in the vial, which is why even the no-DAC version lasts minutes rather than seconds. The albumin linker is what stretches minutes into days, and it is the single feature that splits CJC-1295 into two drugs.

CJC-1295 came from ConjuChem Biotechnologies, a Montreal company whose whole platform was clipping short-lived drugs onto albumin. Its lead GHRH candidate produced days-long GH and IGF-1 elevation in early human studies, an impressive result. Then a patient in the phase II trial died of a cardiovascular event, the study was halted, and the company ended development. The card pairs the promise with that abrupt stop.

The honest reading is careful on both sides. The phase I data are real and show genuine pharmacology, but the phase II death had contested causality and stopped the program before any efficacy readout. What we are left with is a promising short chapter, not a finished book, and no regulated sponsor has reopened it since.

If you remember one thing from this course, make it this: CJC-1295 with DAC and CJC-1295 without DAC are not two doses of the same drug, they are two different drugs. They differ in half-life by roughly 300 times and in typical dose by about tenfold. The two panels put them side by side so the gap is unmistakable.

This is not a pedantic footnote. A person who buys "CJC-1295" without knowing which version they have can be off by an order of magnitude, and vendor mislabeling is a documented problem. Every dosing, pharmacology, and safety statement later in the course is tagged by variant for exactly this reason.

CJC-1295 sits in an unusual spot: its short-term pharmacology is genuinely well documented, but almost everything people actually want it for, body composition and long-term benefit, has never been tested in a controlled trial. The tiers below separate what is measured from what is merely hoped, and the gauge scores the flagship claim.

The gap between the top tier and the bottom is the entire point. The pharmacology is real and the mechanism is coherent, but the leap from a documented hormone rise to a promised physical outcome is exactly where the evidence runs out. Keeping those apart is what separates honest education from marketing copy for this drug.

A handful of confident claims dominate the online conversation about CJC-1295. Held against the evidence, most are not flatly false so much as overstated: a real short-term effect gets rounded up into a guaranteed outcome. Tap each claim to see the honest verdict and its evidence tier.

Notice the recurring pattern. The strongest claim, days-long IGF-1 elevation, is exactly the one with trial data behind it, while the popular muscle-and-safety claims are the ones running ahead of the evidence. Learning to attach the right tier to each statement is the core skill this course builds.